Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.

Stoke Therapeutics, Inc.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://www.stoketherapeutics.com
Founded2017
Disease Focus
Development Stage
STOCK CODENon Listed
Address3 Preston Court, Suite 102, MA, 01730BedfordUnited States
3 Preston Court, Suite 102, MA, 01730
Bedford
United States
Contact Number+1 781-430-8200
+1 781-430-8200
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/stoke-therapeutics” connections=”true” suffix=””]